Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2036-06-08 | Direct | 6,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 6,000 · Balance 6,000 F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:30 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001811463-26-000002 · form4-06112026_040609.xml · derivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 21:15 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001415889-25-011112 · form4-04212025_050413.xml · derivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:24 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001415889-24-015756 · form4-06062024_080626.xml · derivative · entry 2 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2034-06-04 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:24 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 150,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015756 · form4-06062024_080626.xml · nonDerivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,085 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 4, 2025 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 44,961 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-23-034330 · doc4.xml · derivative · entry 2 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,961 Underlying: Common Stock · 44,961 shares Expires 2033-06-01 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 32,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034330 · doc4.xml · nonDerivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,438 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 1, 2024 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 16,996 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-22-034627 · doc4.xml · derivative · entry 2 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,996 Underlying: Common Stock · 16,996 shares Expires 2032-06-02 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 11,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034627 · doc4.xml · nonDerivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,076 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 2, 2023 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 10,800 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0001209191-21-038765 · doc4.xml · derivative · entry 2 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2031-06-03 F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 23:34 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038765 · doc4.xml · nonDerivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's nonemployee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:51 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $17.03 | $0.00 |
DisclosureSEC source: 0001209191-20-039488 · doc4.xml · derivative · entry 1 Shiff Susan Ph.D. · CIK 0001811463 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2030-06-26 F1 · derivative.exercise_date: The option shall vest and become exercisable in twelve (12) equal quarterly installments beginning on September 26, 2020 such that the option will be fully vested and exercisable on June 26, 2023, subject to the Reporting Person's continued service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.